Molecular biology of lung cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Thoracic Disease

• Publication date

  2013-10-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3978/j.issn.2072-1439.2013.08.03PMID 24163741PMCID PMC3804875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

  2013cited by this paper
• Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients

  2013cited by this paper
• Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

  2013cited by this paper
• Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology

  2013cited by this paper
• Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

  2013cited by this paper
• Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma

  2013cited by this paper
• Genomic landscape of non-small-cell lung cancer in smokers and never-smokers

  2013cited by this paper
• New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

  2013cited by this paper
• MET as a possible target for non-small-cell lung cancer.

  2013cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

  2012cited by this paper
• Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012influential reference
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

  2012influential reference
• Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

  2012cited by this paper
• Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• Chipping away at the lung cancer genome

  2012cited by this paper
• Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

  2012cited by this paper
• Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

  2012cited by this paper
• Genomic landscape of non-small cell lung cancer in smokers and never-smokers.

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012influential reference
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Genetic Changes in Squamous Cell Lung Cancer: A Review

  2012cited by this paper
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

  2011cited by this paper
• Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

  2011influential reference
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

  2011cited by this paper
• Targeting Anaplastic Lymphoma Kinase in Lung Cancer

  2011cited by this paper
• EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

  2011cited by this paper
• Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

  2011cited by this paper
• Genomic medicine in non‐small cell lung cancer: Paving the path to personalized care

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)

  2011cited by this paper
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

  2011influential reference
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

  2011cited by this paper
• TP53 Mutations in Nonsmall Cell Lung Cancer

  2011cited by this paper
• Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.

  2011cited by this paper
• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.

  2010cited by this paper
• The mutation spectrum revealed by paired genome sequences from a lung cancer patient

  2010cited by this paper
• EML4-ALK Fusion Gene Assessment Using Metastatic Lymph Node Samples Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

  2010cited by this paper
• A small step towards personalized medicine for non-small cell lung cancer.

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009cited by this paper
• Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2009cited by this paper
• EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

  2009cited by this paper
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

  2009cited by this paper
• EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset

  2009cited by this paper
• Targeting the RET Pathway in Thyroid Cancer

  2009cited by this paper
• Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

  2009cited by this paper
• Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

  2009cited by this paper
• Impact of EGFR mutation analysis in non-small cell lung cancer.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

  2009cited by this paper
• The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

  2009cited by this paper
• MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

  2008cited by this paper
• Molecular genetics of lung cancer in people who have never smoked.

  2008cited by this paper
• Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

  2008cited by this paper
• Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

  2008cited by this paper
• Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• PIK3CA mutations and copy number gains in human lung cancers.

  2008cited by this paper
• Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

  2008cited by this paper
• Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008influential reference
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

  2008cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

  2008cited by this paper
• STEREOTACTIC RADIATION THERAPY WORKSHOP Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• LKB1 gene mutations in Japanese lung cancer patients

  2007cited by this paper
• Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

  2007cited by this paper
• Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

  2007cited by this paper
• Prevalence and specificity of LKB1 genetic alterations in lung cancers

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

  2007cited by this paper
• Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

  2007cited by this paper
• The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

  2006cited by this paper
• PIK3CA mutation status in Japanese lung cancer patients.

  2006cited by this paper
• Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

  2006cited by this paper
• Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

  2006cited by this paper

• Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

  2026cites this paper
• Therapy gone viral: Exploring the use of oncolytic viruses in non-small cell lung cancer immunotherapy.

  2025cites this paper
• Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer

  2025cites this paper
• Evaluation of PI3K Levels and miRNA124‐5p Expression Levels in Serum Samples from Patients With Lung Cancer

  2025cites this paper
• Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer

  2025cites this paper
• CircPTK2 enhances non‐small cell lung cancer proliferation by inhibiting cellular senescence through stabilizing NFYA and elevating FOXM1

  2025cites this paper
• Role of nitric oxide, prostaglandins, thromboxanes and endothelins in lung cancer: An overview

  2025cites this paper
• Diagnostic tools in respiratory medicine (Review)

  2025cites this paper
• AMBRA1 Inhibits Non‐Small Cell Lung Cancer Progression Through miR‐1178/p53/CDK2‐Regulated Cell Cycle Arrest

  2025cites this paper
• Establishing a threshold for maximum standardized uptake value on 18F-fluorodeoxyglucose PET/CT to predict high-grade lung adenocarcinoma and its prognostic significance

  2025cites this paper
• Interplay Between Traditional and Scientific Knowledge: Phytoconstituents and Their Roles in Lung and Colorectal Cancer Signaling Pathways

  2025cites this paper
• Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)

  2025cites this paper
• Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence

  2025cites this paper
• Topological radiogenomics based on persistent lifetime images for identification of epidermal growth factor receptor mutation in patients with non-small cell lung tumors

  2024cites this paper
• Identification of Two Subtypes with Distinct Immune Features in Lung Adenocarcinoma by Utilizing Immune and Metabolism-Related Genes to Assist Immunotherapy.

  2024cites this paper
• AutoCancer as an automated multimodal framework for early cancer detection

  2024cites this paper
• Comparative Analysis of Vitamin D, Folic Acid, and Antioxidant Minerals in Various Stages of Lung Cancer

  2024cites this paper
• Novel Transcriptional and DNA Methylation Abnormalities of SORT1 Gene in Non-Small Cell Lung Cancer

  2024cites this paper
• The molecular mechanisms of various long non-coding RNA (lncRNA) in human lung tumors: Shedding light on the molecular mechanisms.

  2024cites this paper
• NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy

  2024cites this paper
• Current management of uncommon EGFR mutations in non-small cell lung cancer.

  2024cites this paper
• Beneficial implications of adjuvant chemotherapy for stage IB lung adenocarcinoma exhibiting elevated SUVmax in FDG-PET/CT: a retrospective study from a single center

  2024cites this paper
• Cellular and molecular aspects of drug resistance in cancers

  2024cites this paper
• The current (and possible future) role of opioid analgesia in lung cancer surgery.

  2024cites this paper
• Enhancing Immune Response in Non-Small-Cell Lung Cancer Patients: Impact of the 13-Valent Pneumococcal Conjugate Vaccine

  2024cites this paper
• Role of Nanoformulations in the Treatment of Lung Cancer.

  2024cites this paper
• KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells

  2024cites this paper
• Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

  2023cites this paper
• Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R

  2023cites this paper
• Establishment and validation of nomograms for predicting survival of lung invasive adenocarcinoma based on the level of pathological differentiation: a SEER cohort-based analysis

  2023cites this paper
• Sexual dimorphism in chronic respiratory diseases

  2023cites this paper
• Dietary Phytochemicals as Potential Chemopreventive Agents against Tobacco-Induced Lung Carcinogenesis

  2023cites this paper
• Systematically analyzed molecular characteristics of lung adenocarcinoma using metabolism-related genes classification

  2023cites this paper
• Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine.

  2023cites this paper
• Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

  2023cites this paper
• Circ_0060937 Contributes to the Development of Lung Cancer via Positively Regulating LAD1 Expression by Binding to miR-1304-5p

  2023cites this paper
• MAPKAPK5-AS1/miR-515-5p/CAB39 Axis Contributes to Non-small Cell Lung Cancer Cell Proliferation and Migration

  2023cites this paper
• Clinicopathological significances of cribriform pattern in lung adenocarcinoma.

  2023cites this paper
• Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma

  2023cites this paper
• Lung cancer associated with combustion particles and fine particulate matter (PM2.5) - The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor (AhR)

  2023cites this paper
• The Structural Proteins of Membrane Rafts, Caveolins and Flotillins, in Lung Cancer: More Than Just Scaffold Elements

  2023cites this paper
• Effective lung cancer control: An unaccomplished challenge in cancer research

  2023cites this paper
• Correlation of TIMP1-MMP2/MMP9 Gene Expression Axis Changes with Treatment Efficacy and Survival of NSCLC Patients

  2023cites this paper
• A retrospective study of postoperative targeted therapy in ALK-positive lung cancer

  2023cites this paper
• The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity

  2023cites this paper
• Deciphering the molecular mechanistic paths describing the chemotherapeutic potential and epigenetic regulation of curcumin in lung cancer: a mini review

  2023cites this paper
• Anti-lung Cancer Marine Compounds: A Review

  2022cites this paper
• Role of Periostin Expression in Non-Small Cell Lung Cancer: Periostin Silencing Inhibits the Migration and Invasion of Lung Cancer Cells via Regulation of MMP-2 Expression

  2022cites this paper
• Novel long non‐coding RNA CYB561‐5 promotes aerobic glycolysis and tumorigenesis by interacting with basigin in non‐small cell lung cancer

  2022cites this paper
• Novel targeted therapies for advanced non-small lung cancer.

  2022cites this paper
• Circular RNA circENTPD7 suppresses the accumulation of PTEN to promote cell proliferation in non-small cell lung cancer

  2022cites this paper
• Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.

  2022cites this paper
• Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions

  2022cites this paper
• Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC

  2022cites this paper
• Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk

  2022cites this paper
• Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma.

  2022cites this paper
• Multicenter Evaluation of the Idylla GeneFusion in Non-Small-Cell Lung Cancer.

  2022cites this paper
• In Vitro Anticancer Activity of Two Ferrocene-Containing Camphor Sulfonamides as Promising Agents against Lung Cancer Cells

  2022cites this paper
• Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.

  2022cites this paper
• Developing dietary interventions as therapy for cancer

  2022cites this paper
• Genomic landscape of lung adenocarcinomas in different races

  2022cites this paper
• Epstein–Barr Virus Infection in Lung Cancer: Insights and Perspectives

  2022cites this paper
• Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application

  2022cites this paper
• RNF115 promotes lung adenocarcinoma through Wnt/β-catenin pathway activation by mediating APC ubiquitination

  2021cites this paper
• Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information

  2021cites this paper
• Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review

  2021cites this paper
• Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis

  2021cites this paper
• Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

  2021cites this paper
• CircVAPA exerts oncogenic property in non‐small cell lung cancer by the miR‐876‐5p/WNT5A axis

  2021cites this paper
• CRISPR and KRAS: a match yet to be made

  2021cites this paper
• Ferroptosis in Lung Cancer: From Molecular Mechanisms to Prognostic and Therapeutic Opportunities

  2021cites this paper
• Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases.

  2021cites this paper
• Integration of data from the cell-based ERK1/2 ELISA and the Comparative Toxicogenomics Database deciphers the potential mode of action of bisphenol A and benzo[a]pyrene in lung neoplasm.

  2021cites this paper
• Detection of ALK Gene Rearrangements in Non-Small Cell Lung Cancer by Immunocytochemistry and Fluorescence in Situ Hybridization on Cytologic Samples

  2021cites this paper
• Lung Cancer Stem Cells—Origin, Diagnostic Techniques and Perspective for Therapies

  2021cites this paper
• Virus Nanoparticles & Different Nanoparticles Affect Lung Cancer- A New Approach

  2021cites this paper
• A549 in-silico 1.0: A first computational model to simulate cell cycle dependent ion current modulation in the human lung adenocarcinoma

  2021cites this paper
• MicroRNAs: Key Regulators in Lung Cancer.

  2021cites this paper
• CRISPER/CAS System, a Novel Tool of Targeted Therapy of Drug-Resistant Lung Cancer

  2021cites this paper
• Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

  2021cites this paper
• mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy.

  2021cites this paper
• Exploring the Role and Mechanism of pAMPKα-Mediated Dysregulation of Brf1 and RNA Pol III Genes

  2021cites this paper
• Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma

  2021cites this paper
• LncRNA PSMG3AS1 promotes proliferation of non-small cell lung cancer cells by sponging miR-613 to upregulate SphK1

  2021cites this paper
• Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations

  2021cites this paper
• Polyphyllin I promotes cell death via suppressing UPR-mediated CHOP ubiquitination and degradation in non-small cell lung cancer.

  2021cites this paper
• Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone

  2021cites this paper
• LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis

  2020cites this paper
• Efavirenz induces DNA damage response pathway in lung cancer

  2020cites this paper
• Nutritional Support in Lung Cancer Patients: The State of the Art.

  2020cites this paper
• Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma

  2020cites this paper
• EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer

  2020cites this paper
• CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells

  2020cites this paper
• Solubility Enhancement of Methotrexate by Solid Nanodispersion Approach for the Improved Treatment of Small cell Lung Carcinoma.

  2020cites this paper
• Multi-scale supervised clustering-based feature selection for tumor classification and identification of biomarkers and targets on genomic data

  2020cites this paper
• MiR-449b-5p targets lncRNA PSMG3-AS1 to suppress cancer cell proliferation in lung adenocarcinoma

  2020cites this paper
• Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma

  2020cites this paper
• LUNG CANCER - STATISTICAL ANALYSIS DATA IN A 5 YEAR PERIOD IN BITOLA, REPUBLIC OF NORTH MACEDONIA

  2020cites this paper
• MicroRNA genetic signature in non-small cell lung cancer (NSCLC) Egyptian patients

  2020cites this paper
• Long non‐coding RNA CASC19 facilitates non‐small cell lung cancer cell proliferation and metastasis by targeting the miR‐301b‐3p/LDLR axis

  2020cites this paper